Related Experiment Video
Updated: Nov 19, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
Severity of Non-B and Non-C Hepatitis Versus Hepatitis B and C Associated Chronic Liver Disease: A Retrospective,
Muhammad Sohaib Asghar1, Muhammad Nadeem Ahsan2, Uzma Rasheed3
1Internal Medicine, Dow University of Health Sciences, Karachi, PAK.
Insights
This study found that non-hepatitis B, C associated Chronic Liver Disease (CLD) has a higher mortality risk in severe stages (Child-Pugh class C), indicated by higher MELD scores. Biochemical markers also correlate with CLD severity across different etiologies.
Area of Science:
- Hepatology
- Internal Medicine
- Clinical Research
Background:
- Chronic Liver Disease (CLD) has diverse causes including viral hepatitis, alcohol abuse, and non-alcoholic fatty liver disease.
- The Child-Pugh scoring system assesses cirrhosis prognosis and mortality risk.
- Understanding etiological differences in CLD severity and mortality is crucial for patient management.
Purpose of the Study:
- To evaluate mortality risks associated with various CLD etiologies.
- To identify biochemical markers correlating with CLD severity.
- To compare Model for End-Stage Liver Disease (MELD) scores across CLD groups and Child-Pugh classifications.
Main Methods:
- Retrospective study of 167 CLD patients (July-Dec 2019).
- Etiologies categorized into hepatitis B, C-CLD and non-hepatitis B, C-CLD groups.
- Statistical analysis included independent sample t-tests and chi-square/Fisher's exact tests (p<0.05 significance).
Main Results:
- No significant gender or age differences between CLD groups.
- Non-hepatitis B, C-CLD showed significant association with comorbidities like diabetes and hypertension.
- While bilirubin and creatinine levels were higher in non-hepatitis B, C-CLD, MELD scores were significantly higher in Child-Pugh class C non-hepatitis B, C-CLD patients.
Conclusions:
- Non-hepatitis B, C-CLD presents as milder in early stages (Child-Pugh A) but carries increased mortality risk in advanced stages (Child-Pugh C).
- MELD scores are significantly higher in severe non-hepatitis B, C-CLD, indicating greater mortality risk.
- The study identified key biochemical markers associated with CLD severity across different etiologies.
Abstract:
Background and objectives Chronic liver disease (CLD) encompasses a variety of etiologies, and the infectious causes are mainly hepatitis B and hepatitis C virus. Chronic alcohol abuse and non-alcoholic fatty liver disease also have a major contribution to CLD. The Child-Pugh scoring system indicates the probable prognosis and mortality risk of a patient with cirrhosis. The primary objective of this research is to observe the mortality risks of CLD caused by a variety of etiologies mentioned above. The secondary objective is to determine the biochemical markers that are correlating with the severity of the study groups. Another aim was to determine the Model for End-Stage Liver Disease (MELD) scoring of each study group predicting the severity of disease among the Child-Pugh classification. Materials and methods We broadly classified the etiologies into two study groups: (1) hepatitis B, C associated CLD (hepatitis B, C--CLD) and (2) non-hepatitis B, C associated CLD (non-hepatitis B, C-CLD). This study was conducted as a descriptive, retrospective study involving patients admitted to the Gastroenterology Department at Dow University Hospital between July 2019 and December 2019. All patients who met the inclusion criteria were included in the study in order to document their levels of severity markers of CLD. A total of 167 individuals met the inclusion criteria, and the sampling was done through non-probability consecutive methods. All continuous variables were described as mean and standard deviations, which were then compared using an independent sample t-test. The comparison of categorical data was done either using the chi-square test or Fisher's exact test accordingly. A p-value of <0.05 was considered statistically significant (two-tailed). Results The mean age of the study population was 51.83 ± 13.67, with no difference in gender and type of CLD. The frequent co-morbidities (other than CLD) found in the study population were diabetes, hypertension, ischemic heart disease, and chronic kidney disease, with most of them having significant association with non-hepatitis B, C-CLD. Both types of CLD had equal gender proportion (p=0.708). Among the study groups, 56.28% (n=94) had hepatitis B, C-CLD, out of which 18 (19%) belonged to Child-Pugh class A, 36 (38%) to Child-Pugh class B, and 40 (43%) to Child-Pugh class C, whereas 43.72% (n=71) had non-hepatitis B, C-CLD, comprising of 13% (n=10) of Child-Pugh class A patients, 42% (n=31) of Child-Pugh class B patients, and 44% (n=32) of Child-Pugh class C patients (p=0.631). Bilirubin levels (p=0.055), serum creatinine (p=0.201), and International normalized ratio (INR) are found higher in non-hepatitis B, C-CLD (p=0.312), whereas thrombocytopenia was more likely to be associated with hepatitis B, C-CLD (p=0.205). Hyponatremia was slightly associated with non-hepatitis B, C-CLD (p=0.281). The mean MELD score was comparable among the two study groups in both Child-Pugh classes A and B, but in Child-Pugh class C it was significantly higher in non-hepatitis B, C-CLD patients as compared to hepatitis B, C--CLD (p=0.006). Conclusion Non-hepatitis B, C-CLD was proved to be milder in Child-Pugh class A as compared to hepatitis B, C-CLD, but its mortality risk increases with severity, as mean MELD score was found significantly higher in Child-Pugh class C. Our research was able to identify severe biochemical markers in both types of CLD.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

